The ophthalmic solution is commonly used to help manage the symptoms of allergic conjunctivitis, encompassing both seasonal (hay fever) and perennial (year-round) forms. The medication is relevant for managing symptom clusters that may become intense or disruptive, such as visible eye redness, excessive tearing, and severe eye itching (pruritus).

The primary supportive use is related to prevention; it is often used during phases when symptoms become more noticeable, providing support that contributes to easing the overall symptom burden. Mylan Allercrom 2% is also considered relevant in contexts involving specialized, chronic allergic conditions, including Vernal Keratoconjunctivitis (VKC), and is applied in situations where patients experience persistent discomfort and recurrent manifestations like eye grittiness and soreness.

“This supportive therapy may assist with supporting functional stability and contributes to easing the overall symptom load.”

Quick Fact: Symptom Management Focus

Indications Managed

This treatment is commonly used to address the symptoms associated with: seasonal allergic conjunctivitis, perennial allergic conjunctivitis, and certain severe, recurrent forms like Vernal Keratoconjunctivitis.

Regulatory References

1. NIH MedlinePlus Drug Information

Official Eligibility Rules for Mylan Allercrom 2%

Regulatory documents define clear population rules for the use of Mylan Allercrom 2% (Sodium Cromoglycate ophthalmic solution), centered on age restrictions, hypersensitivity, and reproductive status.

Eligibility Domain	Regulatory Status	Population Affected
Absolute Contraindication	Prohibited	Patients with known hypersensitivity to Sodium Cromoglycate or any excipients.
Pediatric Use	Not Recommended/Contraindicated	Use is not recommended in children under 6 years of age and is contraindicated in children under 2 years of age in some regions.
Standard Use	Allowed	Adults and adolescents. Use is established in children over 6 years.
Pregnancy/Lactation	Conditional/Caution	Use should be with caution and only if clearly needed. No specific systemic risk is known due to minimal absorption.
Contact Lenses	Conditional Restriction	Soft contact lens wearers must remove lenses before application and wait at least 15 minutes before reinsertion due to the presence of the preservative benzalkonium chloride.

Due to its minimal systemic absorption, the official prescribing information for the ophthalmic solution does not document specific restrictions related to hepatic or renal impairment.

Interactions with Other Medicines and Products

Absence of Systemic Pharmacokinetic Interactions

Official regulatory information documents that Sodium Cromoglycate Ophthalmic Solution has no known interactions with other systemic medicinal products. This is attributed to the product's poor systemic absorption; less than 0.07% of the active ingredient enters the bloodstream. Because of this negligible systemic exposure, the regulatory profile concludes that the medicine does not engage in clinically significant pharmacokinetic interactions, such as those mediated by CYP enzymes, nor does it affect the exposure levels (AUC/Cmax) of other orally administered drugs. No interactions with food, alcohol, or herbal products are documented in the official prescribing information for this eye drop formulation.

---

Documented Pharmacodynamic and Procedural Restrictions

While there are no negative drug–drug interactions, regulatory labels document a permissible co-administration pattern and a specific product-related timing rule.

• Permitted Co-administration: The use of topical corticosteroids is permitted concomitantly with Sodium Cromoglycate eye drops, confirming the absence of a negative pharmacodynamic interaction between these agents.

• Timing Restriction (Product-related): A mandatory procedural constraint exists involving the preservative Benzalkonium Chloride and Contact Lenses. Soft contact lenses must be removed before the administration of the drops and may not be reinserted for at least 15 minutes following use, as the preservative can bind to and be absorbed by the lens material. This is the only mandatory administration separation rule specified in official labeling.

Regulation of Mast Cell Degranulation

Mylan Allercrom 2% contains cromolyn sodium, a compound classified as a mast cell stabilizer. Its mechanism involves engaging pathways within immune cells to influence feedback regulation and maintain cellular integrity. The substance specifically impedes the process of degranulation in sensitized mast cells when they are exposed to specific antigens. This action is mediated by an effect on calcium flux across the mast cell membrane, which is a critical signal required for the release of stored mediators.

---

Inhibition of Inflammatory Mediator Release

By stabilizing the mast cell membrane and modifying intracellular molecular steps, cromolyn sodium prevents the rapid discharge of preformed and newly synthesized inflammatory and vasoactive chemicals. This cascade suppression primarily stops the immediate release of primary mediators, including histamine and leukotrienes. The net consequence is a reduction of mediator activity in the local tissue microenvironment, facilitating a subsequent modulation of physiological responses resulting from these signaling patterns.

Official Administration Guidelines for Mylan Allercrom 2%

The use of Mylan Allercrom 2% (Sodium Cromoglycate ophthalmic solution) follows specific application patterns, emphasizing a structured and continuous administration schedule.

Dosing and Frequency

The medicine is administered via the topical ophthalmic route only. The standard dose for adults and children is one or two drops instilled into each eye. This quantity is typically given four times a day (four times daily) at regularly spaced intervals to maintain the prophylactic effect. The frequency may be increased up to six times daily if necessary.

Administration Context and Timing

Therapy with Sodium Cromoglycate is fundamentally prophylactic, meaning its use should commence before the anticipated exposure to known allergens, such as prior to the start of the allergy season. The continuous administration throughout the risk period is crucial for the drug to function as intended. If a dose is missed, it should be applied as soon as the lapse is noticed, and the regular dosing schedule should then be resumed. Standard practice involves not doubling doses to compensate for a missed application.

Procedural Steps and Handling

Certain constraints apply to the proper use of the drops. Soft contact lenses must be removed before the solution is instilled. A waiting period of at least 15 minutes is necessary before reinserting soft contact lenses. This requirement ensures the solution's contact with the eye surface and manages the interaction with preservatives in the product. The treatment is generally maintained for the duration of the patient's exposure to the allergen.

Research Evidence / Overview of Studies for Mylan Allercrom 2%

Evidence for Use in Seasonal and Perennial Allergic Conjunctivitis

The research base includes Randomized Controlled Trials (RCTs) and controlled comparative studies, with data pooled and analyzed in Systematic Reviews and meta-analyses. This research was applied in studies examining patient-reported experiences related to seasonal and perennial allergic eye conditions. Researchers examined outcomes related to physical discomfort, such as eye itching and watering, and objective clinical signs such as conjunctival redness.

Studies report how symptoms evolved in the observed populations over observation periods typically lasting four to six weeks. Meta-analyses contribute to the broader evidence landscape where patient-reported outcomes describing perceived discomfort were analyzed in comparison to placebo. The overall evidence for this indication was observed in some studies to have limitations, including modest sample sizes in many older trials and heterogeneity (variability) in results.

Evidence for Use in Chronic Allergic Conditions (Vernal Keratoconjunctivitis)

Mylan Allercrom 2% was evaluated in studies exploring short-term symptom changes in more severe and chronic allergic conditions, such as Vernal Keratoconjunctivitis (VKC). These controlled clinical trials primarily monitored changes in severe ocular clinical signs and subjective discomfort. Research also examined outcomes related to inflammatory or irritative states and changes in the use of supplementary ocular corticosteroid drops.

It appears to be the case that some clinical trials may have lacked uniform grading criteria for disease severity. Also, comparative evidence is lacking where newer topical anti-allergic agents were also evaluated.

Research Gaps and Areas of Uncertainty

Research has explored the product's use for specific, defined time intervals, but the standard observation period in many controlled trials was limited to the short or intermediate term. The long-term effects are not fully established, and certainty regarding extended-term outcomes remains low. The body of evidence is also limited in formal, dedicated trials that specifically monitor the experience in very young children (typically those under four years of age).

Key Studies & References

1. Cromolyn Ophthalmic: MedlinePlus Drug Information

Common questions about Mylan Allercrom 2% (FAQ)

---

Q: Can I use Mylan Allercrom 2% if I have liver or kidney problems?

This medicine is poorly absorbed into the bloodstream, with less than 0.07% of the active ingredient entering the body’s general circulation. Due to this minimal systemic absorption, official information suggests that specific restrictions related to liver or kidney impairment are typically not documented.

---

Q: What happens if I miss a dose of the eye drops?

If a dose is missed, the official guidance suggests that it should be applied as soon as the lapse is noticed. The patient is generally advised to then resume the regular dosing schedule and avoid doubling the dose to compensate for the missed application.

---

Q: What is the maximum number of drops I can put in my eyes per day?

The maximum number of drops per eye per day is defined in the product labeling. It is important to follow the maximum limits specified in the official product labeling regarding the total daily number of drops.

---

Q: How long does it take for Mylan Allercrom 2% to start working?

As a preventative (prophylactic) agent, the full benefit is usually not immediate. Symptom response, such as a reduction in common allergic symptoms, has been observed in studies to be evident within two to three days after starting treatment.

---

Q: Can I take Mylan Allercrom 2% with other anti-allergic drugs like oral antihistamines?

Official documents confirm there are no known interactions with other systemic medicinal products. Due to the minimal systemic absorption (less than 0.07%), no clinically significant interactions with orally administered medications, including oral antihistamines, have been documented in official product labeling.

---

Q: Is it normal to feel a stinging sensation when I put the drops in?

A transient (short-lived) stinging or burning sensation immediately after application has been identified in official reports as a frequently reported local event.

---

How to Store and Dispose of Mylan Allercrom 2%?

The storage and disposal of Mylan Allercrom 2% (Sodium Cromoglycate Ophthalmic Solution) must adhere strictly to regulatory guidelines to ensure product stability and safety.

Official Storage Requirements

Condition	Requirement
Temperature	Store at room temperature, typically between 15 - 30 C (Do not freeze).
Protection	Keep the bottle tightly closed and store in the original carton to protect from direct sunlight and heat.
Handling	Do not touch the dropper tip to the eye or any surface to maintain solution sterility.
Child Safety	Keep out of the sight and reach of children.

In-Use Stability and Disposal Rules

This ophthalmic solution has a strict 28-day in-use period; it must be discarded four weeks after first opening, regardless of the amount remaining. The medicine must not be used after the printed expiry date.

Disposal must follow local protocols: medicines should not be disposed of via household waste or wastewater and should be returned to a pharmacist for appropriate handling in accordance with local environmental requirements.